Related references
Note: Only part of the references are listed.Inflammatory Bowel Disease Patients' Willingness to Accept Medication Risk to Avoid Future Disease Relapse
Meenakshi Bewtra et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2015)
Effectiveness and Safety of lmmunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's Disease
Mark T. Osterman et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials
Jennifer L. Jones et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) Study
John W. Baddley et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease
Mamoru Watanabe et al.
JOURNAL OF CROHNS & COLITIS (2014)
Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE
R. Panaccione et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials
Alexander C. Ford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
American Gastroenterological Association Institute Guideline on the Use of Thiopurines, Methotrexate, and Anti-TNF-α Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn's Disease
Jonathan P. Terdiman et al.
GASTROENTEROLOGY (2013)
Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease
S. Schreiber et al.
JOURNAL OF CROHNS & COLITIS (2013)
Rheumatoid Arthritis Disease Activity and Disability Affect the Risk of Serious Infection Events in RADIUS 1
Arthur Weaver et al.
JOURNAL OF RHEUMATOLOGY (2013)
Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)
Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment
Timothy Beukelman et al.
ARTHRITIS AND RHEUMATISM (2012)
Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial
Paul Rutgeerts et al.
GASTROENTEROLOGY (2012)
Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: Results from CARE
Robert Lofberg et al.
INFLAMMATORY BOWEL DISEASES (2012)
Radiation Therapy Modalities for Prostate Cancer
Bruce L. Jacobs et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease
Mamoru Watanabe et al.
JOURNAL OF CROHNS & COLITIS (2012)
Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease
M. A. Kamm et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Recommended Adult Immunization Schedule: United States, 2011
Carol J. Baker et al.
ANNALS OF INTERNAL MEDICINE (2011)
High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis
Karen Au et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial
Remo Panaccione et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY (2011)
Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases
Carlos G. Grijalva et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Risk factors for opportunistic infections in patients with inflammatory bowel disease
Murat Toruner et al.
GASTROENTEROLOGY (2008)
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease:: an open randomised trial
Geert D'Haens et al.
LANCET (2008)
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
W. J. Sandborn et al.
GUT (2007)
Adalimumab induction therapy for Crohn disease previously treated with infliximab - A randomized trial
William J. Sandborn et al.
ANNALS OF INTERNAL MEDICINE (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease
Gauree Gupta et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
SB Hanauer et al.
GASTROENTEROLOGY (2006)